Macular Xanthophylls and ω-3 Long-Chain Polyunsaturated Fatty Acids in Age-Related Macular Degeneration

Arnold, Christin; Winter, Lisa; Fröhlich, Kati; Jentsch, Susanne; Dawczynski, J.; Jahreis, Gerhard; Böhm, Volker

doi:10.1001/jamaophthalmol.2013.2851

Cited by 48 publications

(30 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Because of their lipophilic nature, lutein and zeaxanthin may be trapped in adipose tissue [45], which may contribute to their lower availability in the macular pigment in obese and overweight individuals. A trend for higher lutein and zeaxanthin concentrations in AMD patients with low BMI (18-24) has also been noticed by Arnold et al [43]. A data analysis taking such factors into consideration may provide better insights into the physiological and pathological role of nutritional elements.…”

Section: Discussionmentioning

confidence: 70%

“…Additionally, a comparable MPOD value has been observed in a 12-month RCT conducted to evaluate the effectiveness of a supplementation containing lutein, zeaxanthin, DHA and eicosapentaenoic acid. This combination significantly improved MPOD up to a degree of 0.27 ± 0.12 density units (mean ± SD) in 20 mg/day lutein and 0.23 ± 0.15 density units in 10 mg/day lutein groups [43]. Improvement in MPOD noted in both these cases is much greater than the overall mean effect size of 0.09 (CI: 0.06, 0.11) seen in the meta-analysis, in which effect sizes of six RCTs (lutein vs. placebo) were pooled.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Role of Lutein Supplementation in the Management of Age-Related Macular Degeneration: Meta-Analysis of Randomized Controlled Trials

et al. 2014

View full text Add to dashboard Cite

Objective: The conduct of this meta-analysis aimed at examining the individual role of lutein as a dietary supplement in improving conditions of age-related macular degeneration (AMD) from the data generated from randomized controlled trials (RCTs). Method: The literature search was made in multiple electronic databases. Eligibility criteria were RCTs that recruited AMD patients or individuals at risk and evaluated lutein supplementation efficacy against placebo. The quality of the trials was assessed by using the Jadad scale. The meta-analysis was conducted under the fixed effect model with RevMan software by calculating the mean differences of the changes from baseline of both lutein and placebo groups. Parameters of interest were macular pigment optical density (MPOD) and visual acuity (VA) in logMAR (minimum angle of resolution). Heterogeneity was determined by χ² and I² and publication bias was assessed by visual examination of funnel plots. Results: After following predetermined inclusion and exclusion criteria, five RCTs that recruited 445 participants were selected for the meta-analysis. It has been found that lutein treatment was associated with a significant improvement in MPOD, with mean differences between lutein and placebo groups in the changes from baseline of 0.09 (95% CI: 0.06, 0.12; p < 0.00001). VA also improved with a mean difference between lutein and placebo groups in the changes from baseline of −0.04 (95% CI−0.07, 0.00; p = 0.05). Statistical heterogeneity was not apparent. Conclusion: A statistically highly significant effect of lutein supplementation has been observed for improving the MPOD, whereas the improvement in VA was milder. A daily dose of 10 mg was found as effective as higher doses in this meta-analysis. However, the number of input studies is not adequate for conclusive evidence.

show abstract

Section: Discussionmentioning

confidence: 70%

Section: Discussionmentioning

confidence: 99%

Role of Lutein Supplementation in the Management of Age-Related Macular Degeneration: Meta-Analysis of Randomized Controlled Trials

et al. 2014

View full text Add to dashboard Cite

show abstract

“…The xanthophyll carotenoids, such as lutein and zeaxanthin, are concentrated at the central fovea of the macula [2]. Macular pigment reportedly shows strong absorption of wavelengths shorter than 520 nm [3].…”

Section: Introductionmentioning

confidence: 99%

Characteristics of Hyperautofluorescent Choroidal Vessels Using Fundus Camera Type Short-Wavelength Autofluorescence

Shinojima

Mori²,

Nakashizuka³

et al. 2016

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To clarify differences between eyes showing hyperautofluorescent choroidal vessels in both nasal and temporal, or only the nasal, portions of the fundus using fundus autofluorescence. Methods: Nineteen eyes with hyperautofluorescent vessels in both nasal and temporal portions (group 1) and 17 only the nasal portion (group 2) of the fundus were studied. Choroidal and retinal thicknesses (foveal, and nasal and temporal 3,000 µm from the fovea), axial length, and refraction were compared between the two groups. Results: In group 1, the average foveal, nasal, and temporal choroidal thicknesses (mean ± SD) were 69.0 ± 30.9, 57.1 ± 18.7, and 88.3 ± 30.4 μm, retinal thicknesses 170.1 ± 48.5, 221.9 ± 46.5, and 209.5 ± 37.9 μm, axial length 28.2 ± 2.2 mm, and refraction -9.9 ± 5.9 dpt. In group 2, the respective values were 174.8 ± 43.0, 80.5 ± 20.9, and 173.5 ± 46.1 μm, 213.4 ± 29.8, 278.3 ± 20.2, and 252.8 ± 19.6 μm, 24.2 ± 1.4 mm, and -1.8 ± 3.8 dpt. There were significant between-group differences for all items (p < 0.05). Conclusions: Fundus autofluorescence tends to be associated with the detection of hyperautofluorescent choroidal vessels in eyes with strong myopia or greater axial length.

show abstract

“…Lutein is one of the main macular pigments and is concentrated at the center of the macula [18][19][20] . Lutein was shown in previous experiments using monkeys to be partially metabolized into meso-zeaxanthin [21] .…”

Section: Discussionmentioning

confidence: 99%

A Multicenter Randomized Controlled Study of Antioxidant Supplementation with Lutein for Chronic Central Serous Chorioretinopathy

et al. 2017

View full text Add to dashboard Cite

Purpose: To investigate functional and morphological changes in patients with chronic central serous chorioretinopathy after supplementation with antioxidants containing lutein or a placebo. Procedures: One hundred eyes of 100 patients were randomly divided into 2 groups, one taking tablets with lutein plus other antioxidants and the other taking a placebo for 6 months. Best-corrected visual acuity (BCVA) and the subfoveal fluid height on optical coherence tomography were measured. Results: Seventy-nine patients (37 in the supplementation and 42 in the placebo group) completed the 6-month follow-up. In the supplementation group, mean BCVA showed significant improvement (p = 0.003), while there was no significant change in the placebo group (p = 0.589). The mean subfoveal fluid height was significantly reduced, by 28.6%, in the supplementation group (p = 0.028), in contrast to 3.3% in the placebo group (p = 0.898). Conclusions: Antioxidant supplementation significantly reduced subfoveal fluid height. The impacts of antioxidant supplementation on BCVA remain to be elucidated in future studies.

show abstract

Macular Xanthophylls and ω-3 Long-Chain Polyunsaturated Fatty Acids in Age-Related Macular Degeneration

Cited by 48 publications

References 40 publications

Role of Lutein Supplementation in the Management of Age-Related Macular Degeneration: Meta-Analysis of Randomized Controlled Trials

Role of Lutein Supplementation in the Management of Age-Related Macular Degeneration: Meta-Analysis of Randomized Controlled Trials

Characteristics of Hyperautofluorescent Choroidal Vessels Using Fundus Camera Type Short-Wavelength Autofluorescence

A Multicenter Randomized Controlled Study of Antioxidant Supplementation with Lutein for Chronic Central Serous Chorioretinopathy

Contact Info

Product

Resources

About